Affinimark Technologies is a life sciences firm focused on developing rapid response, lateral flow-based devices for the diagnosis of severe medical conditions.
Their first diagnostic under development, Cerebrostrip, is designed to detect the existence of cerebrospinal fluid leaks, potentially a $300 million-plus annual U.S. market. Unlike the current prevailing technology, Cerebrostrip would provide on-the-spot diagnosis through a device that operates much like a pregnancy test.
A second product, Prostalent, is being developed to offer similar convenience and accuracy in the diagnosis of early-stage prostate cancer, a $1.5+ billion domestic market with a targeted population of over 55 million men.
The company is seeking up to $2 million in seed and early-stage funding, and will be negotiating for equity or strategic partnership funding to cover expenses through the next four years, estimated at $10-15 million. |
